scholarly journals СТРАТЕГІЯ ТА ПРИНЦИПИ ТЕРАПІЇ ПАЦІЄНТІВ ІЗ ШИЗОФРЕНІЄЮ І КОМОРБІДНИМИ СЕРЦЕВО-СУДИННИМИ ЗАХВОРЮВАННЯМИ

2019 ◽  
pp. 141-144
Author(s):  
Ye. V. Opryа
Keyword(s):  
Mental Disorder ◽  
Short Form ◽  
Social Performance ◽  
Syndrome Scale ◽  
Sf 36 ◽  
Negative Syndrome ◽  
Performance Scale

Коморбідність психічних розладів із соматичною патологією являє собою одну з провідних та надскладних проблем сучасної психіатричної практики, зокрема в питаннях терапії. Шизофренія є одним із найрозповсюдженіших психічних розладів, що характеризується високою частотою поєднання з соматичною патологією, наявність якої відмічають майже у кожного другого хворого на шизофренію. Мета дослідження – на основі комплексного аналізу клініко-психопатологічних особливостей шизофренії, що поєднана із серцево-судинними захворюваннями, розробити стратегію та принципи її терапії. Матеріали і методи. В якості методів дослідження використовували: клініко-психопатологічний метод, який доповнювали застосуванням клінічної рейтингової шкали позитивної та негативної симптоматик (Positive and Negative Syndrome Scale – PANSS) для оцінки психопатологічних проявів; а також психодіагностичний метод із застосуванням модифікованого варіанта методики Дембо–Рубінштейна для визначення особливостей самооцінки загального стану здоров’я та окремо психічного й фізичного здоров’я; адаптованого варіанта методики SUMD (The Scale to Assess Unawareness of Mental Disorder) для оцінки рівня “інсайту” психічної хвороби; та короткого опитувальника сприйняття хвороби (КОCХ, BIPQ) в адаптації В. М. Ялтонського; шкали особистісного та соціального функціонування (Personal and Social Performance Scale (PSP)) та короткої форми опитувальника про стан здоров’я (The 36-Item Short Form Survey (SF-36) для оцінки якості життя обстежених хворих. Результати досліджень та їх обговорення. У дослідженні обстежено 100 хворих на шизофренію (F20), з яких 50 осіб із наявністю хронічної серцево-судинної патології склали основну групу дослідження, 50 пацієнтів без хронічного соматичного обтяження контрольну. До основної групи залучали пацієнтів із шизофренією і серцево-судинними захворюваннями (ССЗ) тривалістю не менше 3-х років, які на момент дослідження були компенсовані. Пацієнти з постінсультними та постінфарктними станами в дослідження не брали. В структурі серцево-судинної патології хворих основної групи переважали: ішемічна хвороба серця – 64 % та гіпертонічна хвороба – 52 %, також були представлені порушення серцевого ритму – 14 %, кардіоміопатії – 6 %, вади серця (4 %) та варикозне розширення судин (4 %). У більшості випадків спостерігали коморбідність декількох серцево-судинних захворювань одночасно. Висновки. Виділено та описано провідні стратегічні завдання та тактику терапії хворих, що включали: купірування антипсихотичної симптоматики з урахуванням специфіки соматичного стану; опанування навичок контролю соматичного симптому та стресу, а також підвищення соціальної компетентності та соціально-особистісного функціонування пацієнтів. Урахування соматичного стану осіб із коморбідними серцево-судинними захворюваннями дозволяє підвищити рівень їх соціальної компетентності.

scholarly journals Tratamento em regime compulsivo ambulatório: estudo de follow-up após um ano em Portugal

2017 ◽  
pp. 21-9
Author(s):  
Sofia Brissos ◽  
Sofia Brissos ◽  
Gonçalo Sobreira ◽  
João Miguel Oliveira ◽  
Zita Gameiro ◽  
...  
Keyword(s):  
Mental Disorder ◽  
Word Association ◽  
Social Performance ◽  
Digit Span ◽  
Association Test ◽  
Word Association Test ◽  
Syndrome Scale ◽  
Negative Syndrome ◽  
Performance Scale

Enquadramento: Não existem evidências suficientes relativamente ao impacto do tratamento em regime compulsivo ambulatório (TCA). Objetivos: Avaliámos o impacto do TCA ao longo de um ano em sintomas, funcionamento pessoal e social, insight e cognição. Métodos: Análise naturalística, longitudinal, no início e no follow-up após um ano, de 15 pacientes seguidos numa consulta especializada de TCA. Os pacientes foram submetidos a avaliação estandardizada com o Positive and Negative Syndrome Scale (PANSS) (Escala Positiva e Negativa do Síndroma), Personal and Social Performance Scale (PSP) (Escala de Desempenho Pessoal e Social), Berrios-Markova Scale to Assess Unawareness in Mental Disorder (SUMD) (Escala de Avaliação da Falta de Consciência no Distúrbio Mental), Trails A e B, Digit Span, e o Controlled Oral Word Association Test (COWA) (Teste de Associação Verbal Controlada). Resultados: No follow-up houve melhorias significativas no funcionamento pessoal e social (PSP inicial total: média=46,9; follow-up: média=59,3), e nomeadamente nas atividades socialmente úteis incluindo trabalho e estudos (p=0,012) e relações pessoais e sociais (p=0,033). Três pacientes (20%) pontuaram =>69 no PSP, um bom nível de funcionamento. Porém, não verificámos melhorias significativas nos sintomas (PANSS=56,8), insight subjetivo ou objetivo (Berrios-Markova=10,0 e SUMD=11,0), ou desempenho cognitivo. Conclusões: No follow-up após um ano, os pacientes em TCA revelaram melhorias significativas no funcionamento pessoal e social, especificamente nas atividades socialmente úteis incluindo trabalho e estudos e nas relações pessoais e sociais, mas não registaram melhorias nos sintomas, insight e funcionamento cognitivo.

scholarly journals Efficacy and safety of brexpiprazole in patients with schizophrenia presenting with severe symptoms: Post-hoc analysis of short- and long-term studies

2020 ◽  
Vol 34 (8) ◽  
pp. 829-838
Author(s):  
Nicole Meade ◽  
Lily Shi ◽  
Stine R Meehan ◽  
Catherine Weiss ◽  
Zahinoor Ismail
Keyword(s):  
Least Squares ◽  
Social Performance ◽  
Mean Difference ◽  
Syndrome Scale ◽  
Scale Total Score ◽  
Short And Long Term ◽  
Negative Syndrome ◽  
Performance Scale ◽  
Long Term Studies

Background: The treatment of patients with severe schizophrenia symptoms can be complicated and expensive. Aims: The purpose of this study was to evaluate the short- and long-term effects of brexpiprazole in patients with schizophrenia presenting with severe symptoms. Methods: Data were pooled from three six-week, randomized, double-blind, placebo-controlled studies and two 52-week, open-label extension studies. In the short-term studies, 1405 patients received placebo or brexpiprazole 2–4 mg/day; 412 brexpiprazole-treated patients rolled over into the long-term studies and received brexpiprazole 1–4 mg/day. More severe symptoms were defined as a Positive and Negative Syndrome Scale Total score >95 (median score at baseline). Outcomes included change in Positive and Negative Syndrome Scale Total and Personal and Social Performance scale scores. Results: Brexpiprazole improved Positive and Negative Syndrome Scale Total score over 6 weeks among more severely ill patients, with a least squares mean difference versus placebo of −6.76 (95% confidence limits: −9.80, −3.72; p<0.0001; Cohen’s d: 0.43). Brexpiprazole also improved Personal and Social Performance scale score over 6 weeks in more severely ill patients (least squares mean difference: 4.38; limits: 2.14, 6.62; p=0.0001; Cohen’s d: 0.38). Improvement of functioning was greatest in the ‘Self-care’ domain, followed by ‘Personal and social relationships’. Among less severely ill patients, brexpiprazole was superior to placebo on Positive and Negative Syndrome Scale Total and Personal and Social Performance scale at Week 6. Improvements were maintained over 58 weeks. No new safety or tolerability concerns were observed. Conclusions: Brexpiprazole is an efficacious and well-tolerated treatment for schizophrenia in patients with more severe, and less severe, symptoms.

Palmitate de palipéridone à doses flexibles chez des patients non-aigus atteints de schizophrénie après échec d’un autre traitement par antipsychotiques injectables à action prolongée

2013 ◽  
Vol 28 (S2) ◽  
pp. 107-108
Author(s):  
P. Cherubin ◽  
L. Hargater ◽  
B. Bergmans ◽  
A. Bjorner ◽  
H. Knegtering ◽  
...  
Keyword(s):  
Scale Score ◽  
Social Performance ◽  
Syndrome Scale ◽  
Negative Syndrome ◽  
Performance Scale

ObjectifsÉvaluer la tolérance, la sécurité d’emploi et la réponse à un traitement par palmitate de palipéridone (PP) à doses flexibles chez des patients non aigus atteints de schizophrénie, après échec d’un traitement par un autre antipsychotique injectable à action prolongée : décanoate d’halopéridol (Déc-Hal), décanoate de flupentixol (Déc-Fpt), décanoate de fluphénazine (Déc-Flu), zuclopenthixol (Zuc) ou rispéridone à libération prolongée (RIS-LP).MéthodesÉtude internationale, prospective, ouverte, de six mois, chez des patients atteints de schizophrénie, non aigus mais insuffisamment contrôlés par d’autres antipsychotiques injectables à action prolongée.Critères d’évaluationTaux de réponse (amélioration ≥ 20 % du score total à la PANSS [Positive and Negative Syndrome Scale]), score à la PSP (Personal and Social Performance scale), événements indésirables (EIs).RésultatsLes analyses ont été réalisées sur la population en intention de traiter de façon stratifiée pour chaque traitement : 53 patients Déc-Hal, 35 Déc-Fpt, 44 Déc-Flu, 42 Zuc, 56 RIS-LP. Les scores totaux moyens à la PANSS initiale variaient de 67,7 ± 20,3 [RIS-LP] à 75,7 ± 13,2 [Déc-Hal]. Entre 71,4 % [RIS-LP] et 85,7 % [Déc-Fpt] des patients ont terminé l’étude. À la fin de l’étude, 53,7 % [Zuc], 54,7 % [Déc-Hal], 59,1 % [Déc-Flu], 61,1 % [RIS-LP] et 61,8 % [Déc- Fpt] des patients ont vu leur score total à la PANSS diminuer d’au moins 20 %. Les scores moyens de PSP de base étaient de 48,7 [Déc-Hal], 59,6 [Déc-Fpt], 53,5 [Déc-Flu], 52,9 [Zuc] et 60,1 [RIS-LP], et le changement en fin d’étude était respectivement de : 5,2 ; 6,1 ; 6,0 ; 6,4 ; et 5,2 (p ≤ 0,0163 pour tous les traitements). Les EIs rapportés au moins une fois dans tous les sous-groupes : douleur au site d’injection, insomnie, trouble psychotique.ConclusionsLe PP à doses flexibles a été bien toléré et a permis une réponse thérapeutique cliniquement significative chez des patients non aigus atteints de schizophrénie, après échec d’un traitement par d’autres antipsychotiques injectables à action prolongée.

scholarly journals Correlation between the Personal and Social Performance scale (PSP) and the Positive and Negative Syndrome Scale (PANSS) in a Greek sample of patients with schizophrenia

2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Eleni Jelastopulu ◽  
Evangelia Giourou ◽  
Giorgos Merekoulias ◽  
Angeliki Mestousi ◽  
Eleftherios Moratis ◽  
...  
Keyword(s):  
Social Performance ◽  
Syndrome Scale ◽  
Negative Syndrome ◽  
Performance Scale

Predictive factors of functional capacity and real-world functioning in patients with schizophrenia

2015 ◽  
Vol 30 (5) ◽  
pp. 622-627 ◽  
Author(s):  
I. Menendez-Miranda ◽  
M.P. Garcia-Portilla ◽  
L. Garcia-Alvarez ◽  
M. Arrojo ◽  
P. Sanchez ◽  
...  
Keyword(s):  
Predictive Factors ◽  
Functional Capacity ◽  
Real World ◽  
Negative Symptoms ◽  
Social Performance ◽  
Performance Skills ◽  
Predictive Variables ◽  
Syndrome Scale ◽  
Report Data ◽  
Negative Syndrome

AbstractPurposeThis study was performed to identify the predictive factors of functional capacity assessed by the Spanish University of California Performance Skills Assessment (Sp-UPSA) and real-world functioning assessed by the Spanish Personal and Social Performance scale (PSP) in outpatients with schizophrenia.MethodsNaturalistic, 6-month follow-up, multicentre, validation study. Here, we report data on 139 patients with schizophrenia at their baseline visit. Assessment: Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression-Severity (CGI-S), Sp-UPSA and PSP. Statistics: Pearson's correlation coefficient (r) was used to determine the relationships between variables, and multivariable stepwise linear regression analyses to identify predictive variables of Sp-UPSA and PSP total scores.ResultsFunctional capacity: scores on the PSP and PANSS-GP entered first and second at P < 0.0001 and accounted for 21% of variance (R2 = 0.208, model df = 2, F = 15.724, P < 0.0001). Real-world functioning: scores on the CGI-S (B = −5.406), PANSS-N (B = −0.657) and Sp-UPSA (B = 0.230) entered first, second and third, and accounted for 51% of variance (model df = 3, F = 37.741, P < 0.0001).ConclusionIn patients with schizophrenia, functional capacity and real-world functioning are two related but different constructs. Each one predicts the other along with other factors; general psychopathology for functional capacity, and severity of the illness and negative symptoms for real-world functioning. These findings have important clinical implications: (1) both types of functioning should be assessed in patients with schizophrenia and (2) strategies for improving them should be different.

Effets du palmitate de palipéridone sur les symptômes négatifs, la dépression/anxiété, le fonctionnement et les symptômes extrapyramidaux chez des patients souffrant d’une schizophrénie non-aiguë, en échec du traitement par aripiprazole oral

2015 ◽  
Vol 30 (S2) ◽  
pp. S151-S151
Author(s):  
A. Schreiner ◽  
P. Bergmans ◽  
P. Cherubin ◽  
L. Hargarter
Keyword(s):  
Rating Scale ◽  
Extrapyramidal Symptom ◽  
Social Performance ◽  
International Classification Of Functioning ◽  
European Congress ◽  
Syndrome Scale ◽  
Événement Indésirable ◽  
Negative Syndrome ◽  
Symptom Rating

ObjectifÉvaluer l’effet du palmitate de palipéridone (PP) à doses flexibles sur les symptômes négatifs, la dépression/anxiété, le fonctionnement et les symptômes extrapyramidaux chez des patients adultes souffrant de schizophrénie non-aiguë, en échec à un traitement par aripiprazole oral.MéthodesÉtude internationale, prospective, en ouvert de 6 mois.ÉvaluationsVariations entre début d’étude (baseline) et dernière observation rapportée sur la PANSS (Positive and Negative Syndrome Scale), la sous-échelle négative de la PANSS, les facteurs de Marder de la PANSS « symptômes négatifs » et « anxiété/dépression », les échelles de fonctionnement PSP (Personal and Social Performance) et Mini-ICF (Mini International Classification of Functioning) et l’échelle ESRS (Extrapyramidal Symptom Rating Scale).RésultatsQuarante-six patients analysés (73,9 % hommes, âge moyen 34,4 ± 9,4 ans, 78,3 % schizophrénie paranoïde). Parmi les patients, 67,4 % ont terminé l’étude. Avant l’inclusion, la dose moyenne d’aripiprazole oral était de 22,7 ± 10,7 mg/jour. Le score de la sous-échelle négative de PANSS s’est significativement amélioré de 20,3 ± 5,0 (baseline) à 17,3 ± 6,1 (fin d’étude) (variation moyenne = −3,0 ± 5,0 ; IC 95 % = −4,4 ; −1,5 ; p < 0,0001), ainsi que les scores des facteurs de Marder « symptômes négatifs » (de 19,5 ± 5,8 à 16,6 ± 5,9 ; IC95 % = −4,5 ; −1,3, p < 0,0001) et « anxiété/dépression » (de 10,3 ± 3,6 à,5 ± 2,9 ; IC95 % = −3,0 ; −0,6, p = 0,0031). Le score ESRS s’est aussi amélioré de manière significative (de −0,6 ± 3,4 ; IC 95 % = −1,6 ; 0,4, p = 0,0456). Le fonctionnement du patient s’est amélioré de manière significative sur les échelles PSP (de 58,9 ± 13,4 à 62,9 ± 15,2, p = 0,041) et Mini-ICF (de 19,0 ± 7,78 à 16,1 ± 9,84 ; IC 95 % −5,1, −0,7 ; p = 0,0079). Le seul événement indésirable sous traitement rapporté chez ≥ 5 patients a été l’anxiété (n = 6).ConclusionsLa transition d’un échec au traitement par aripiprazole oral à un traitement par PP à doses flexibles chez des patients souffrant de schizophrénie non-aiguë a été bien tolérée et s’est traduit par une amélioration significative des symptômes négatifs, dépressifs, anxieux et des symptômes extrapyramidaux, ainsi que du fonctionnement du patient.Traduction de l’abstract résumé présenté au congrès EPA 2015 (European Congress of Psychiatry, Vienna, Austria, 28–31 March 2015)

scholarly journals Atypical Antipsychotics in the Treatment of Depressive and Psychotic Symptoms in Patients with Chronic Schizophrenia: A Naturalistic Study

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Marco Innamorati ◽  
Stefano Baratta ◽  
Cristina Di Vittorio ◽  
David Lester ◽  
Paolo Girardi ◽  
...  
Keyword(s):  
Depressive Symptoms ◽  
Mental Disorder ◽  
Atypical Antipsychotics ◽  
Depression Scale ◽  
Chronic Schizophrenia ◽  
Psychotic Symptoms ◽  
Naturalistic Study ◽  
Syndrome Scale ◽  
Negative Syndrome

Objectives. The aim of this naturalistic study was to investigate whether treatment with clozapine and other atypical antipsychotics for at least 2 years was associated with a reduction in psychotic and depressive symptoms and an improvement in chronic schizophrenia patients’ awareness of their illness.Methods. Twenty-three adult outpatients (15 men and 8 women) treated with clozapine and 23 patients (16 men and 7 women) treated with other atypical antipsychotics were included in the study. Psychotic symptoms were evaluated using the Positive and Negative Syndrome Scale (PANSS), depressive symptoms were assessed with the Calgary Depression Scale for Schizophrenia (CDSS), and insight was assessed with the Scale to Assess Unawareness of Mental Disorder (SUMD).Results. The sample as a whole had a significant reduction in positive, negative, and general symptoms, whereas the reduction in depression was significant only for patients with CDSS scores of 5 and higher at the baseline. At the follow-up, patients treated with other atypical antipsychotics reported a greater reduction in depression than patients treated with clozapine, but not when limiting the analyses to those with clinically relevant depression.Conclusions. Atypical antipsychotics may be effective in reducing psychotic and depressive symptoms and in improving insight in patients with chronic schizophrenia, with no differences in the profiles of efficacy between compounds.

Amélioration fonctionnelle sous palmitate de paliperidone à doses flexibles chez des patients aigus ou non aigus atteints de schizophrénie, après échec d’un traitement par antipsychotiques oraux

2013 ◽  
Vol 28 (S2) ◽  
pp. 108-108
Author(s):  
L. Hargarter ◽  
B. Bergmans ◽  
P. Cherubin ◽  
A. Bjorner ◽  
H. Knegtering ◽  
...  
Keyword(s):  
International Classification ◽  
Disability And Health ◽  
Syndrome Scale ◽  
Health Rating ◽  
Negative Syndrome ◽  
Performance Scale

ObjectifsÉvaluer l’amélioration fonctionnelle chez des patients atteints de schizophrénie sous palmitate de paliperidone (PP) à doses flexibles après échec d’un traitement par antipsychotiques oraux.MéthodesAnalyse menée dans deux sous-groupes de patients atteints de schizophrénie : aigus (n = 202) et non aigus (n = 593) après échec d’un traitement par antipsychotiques oraux, inclus dans une étude internationale, prospective, de six mois.Critères d’évaluationChangement du score total à la PANSS (Positive and Negative Syndrome Scale), à la PSP (Personal and Psychosocial Performance scale), et à la Mini-ICF-APP (Mini International Classification of Functionality, Disability and Health Rating for Activity and Participation Disorders in Psychological Illnesses).RésultatsLes deux sous-groupes ont présenté une amélioration significative du score total à la PANSS : de 98,5 ± 20,1 à l’inclusion à 67,4 ± 24,0 à la fin de l’étude (diminution moyenne = −31,0 ± 29,0) chez les patients aigus et de 71,5 ± 14,6 à 59,7 ± 18,1 (diminution moyenne = −11,7 ± 15,9) chez les patients non aigus. Cette réponse thérapeutique était associée à une augmentation significative du score total à la PSP de 43,9 ± 15,0 à 62,9 ± 17,1 (amélioration moyenne = 19,0 ± 18,7, p <0,0001) chez les patients aigus, et de 58,1 ± 13,4 à 66,1 ± 15,7 (amélioration moyenne =8,0 ± 14,0, p < 0,0001) chez les patients non aigus. Il existait une amélioration significative du score à la Mini-ICF-APP qui diminuait de 26,8 ± 8,5 à 18,5 ± 9,8 (diminution moyenne = −8,0 ± 10,4, p < 0,0001) chez les patients aigus et de 19,8 ± 7,9 à 15,9 ± 8,8 (diminution moyenne = −4,0 ± 7,5, p < 0,0001) chez les patients non aigus.ConclusionsL’amélioration symptomatique sous PP à doses flexibles chez des patients aigus ou non-aigus atteints de schizophrénie après échec d’un traitement par antipsychotique oral s’est accompagnée d’une amélioration fonctionnelle cliniquement significative.

Development of a Brief form of the Life Skills Profile: The LSP-20

2001 ◽  
Vol 35 (5) ◽  
pp. 677-683 ◽  
Author(s):  
Alan Rosen ◽  
Tom Trauer ◽  
Dusan Hadzi-Pavlovic ◽  
Gordon Parker
Keyword(s):  
Concurrent Validity ◽  
Life Skills ◽  
Short Form ◽  
Reliability And Validity ◽  
Data Sets ◽  
Routine Service ◽  
Individual Care ◽  
Syndrome Scale ◽  
Full Form ◽  
Negative Syndrome

Objective: To develop a brief form of the Life Skills Profile (LSP) that incorporates all five subscales of the full form. Method: A new short form of the LSP (LSP-20) was developed to incorporate all five subscales of the full form. The LSP-20 development was based on a reanalysis of data from previously published studies. These data sets were also reanalysed to determine any differential effects of numbers and percentages of items in the LSP-39, LSP-16 and LSP-20, comparability of scores of the different forms, of test–retest and interrater reliability, and validity of the LSP-20 by comparison with the Positive and Negative Syndrome Scale (PANSS). Results: A twenty-item short form of the LSP-39 (LSP-20) is described whichretains 16 items of an earlier short form but which also reproduces the subscale concerned with disability associated with positive psychotic phenomena. The subscales correlated highly with their counterparts in the full form, interrater and test–retest reliabilities were comparable, and concurrent validity was good. Conclusions: The LSP-20 is a brief form of a widely used instrument that offers equivalent coverage to the full form with sound empirical properties, though unlike the LSP-39, it can be scored in the direction of impairments or strengths. Therefore the LSP-20 may be more suited to routine service disability and aggregated outcome assessments, but less suited than the LSP-39 to detailed research, or to interactive use as part of service user's individual care planning and review.

Long-acting risperidone in stable patients with schizoaffective disorder

2005 ◽  
Vol 19 (5_suppl) ◽  
pp. 22-31 ◽  
Author(s):  
A. Mohl ◽  
K. Westlye ◽  
S. Opjordsmoen ◽  
A. Lex ◽  
A. Schreiner ◽  
...  
Keyword(s):  
Schizoaffective Disorder ◽  
Psychiatric Symptoms ◽  
Drug Induced ◽  
Mood Symptom ◽  
Syndrome Scale ◽  
Sf 36 ◽  
Symptom Domains ◽  
Satisfaction With Treatment ◽  
Long Acting ◽  
Negative Syndrome

Oral and long-acting risperidone has been shown to be effective for acute and maintenance treatment of patients with schizoaffective disorders. The present analysis investigated the efficacy and tolerability of direct transition from other antipsychotics to risperidone long-acting injectable in patients with schizoaffective disorder. Patients aged ≥ 18 years with schizoaffective disorder (DSM-IV), who required a change of medication, received risperidone long-acting injectable 25mg (increased to 37.5 or 50mg, if necessary) every 2 weeks for 6 months. The analysis included 249 patients (47% male; mean age 43 years), of whom 74% completed the 6-month study. Mean scores for the total Positive and Negative Syndrome Scale (PANSS) and all three subscales were significantly reduced from baseline to week 4 (p < 0.001), with further improvements until treatment endpoint. Significant improvements from baseline to endpoint were seen in the mood symptom domains of anxiety/depression (10.4±4.1 vs 8.7±3.9) and uncontrolled hostility/excitement (7.6±3.6 vs 6.9±3.8). Mean Global Assessment of Function (GAF) score improved significantly from 59.4±15.6 at baseline to 66.4±17.7 (p < 0.001) at endpoint. Of 87 patients hospitalized at baseline, 67% were discharged at endpoint. Both quality of life (SF-36) and satisfaction with treatment were improved significantly at endpoint. Total ESRS scores fell progressively throughout the study, and the reduction was already statistically significant (p < 0.001) at 4 weeks. Small but statistically significant (p < 0.001) mean shifts of 1.8% were seen in body weight and Body Mass Index (BMI). Patients with schizoaffective disorder derived several benefits from a change to risperidone long-acting injectable, including reductions in psychiatric symptoms (particularly the mood symptom domains) and a reduction in the severity of drug-induced neurological movement disorders.

Sign in / Sign up

Export Citation Format

Share Document